Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech is registering up to 64,864,864 shares of common stock for resale by selling stockholders, consisting of shares issuable upon exercise of Series F warrants issued in an August 2025 warrant inducement transaction.
Shares outstanding were 49,498,576 as of September 16, 2025. The company will not receive proceeds from resale by the selling stockholders; the company would receive proceeds only if the Warrants are exercised for cash, which at full cash exercise of the 64,864,864 Inducement Warrant Shares would yield gross proceeds of $35.7 million.
Moleculin Biotech, Inc. filed a Form S-8 registration statement to register securities for its 2024 Stock Plan, which will be used to grant equity awards to eligible participants. The company incorporates by reference its existing and future Exchange Act reports, so that ongoing public filings automatically update the information available to plan participants. The document also describes broad indemnification protections for directors, officers, employees and agents under Delaware law, the company’s charter and bylaws, and separate indemnification agreements, supported by directors’ and officers’ liability insurance.
Moleculin Biotech announced updates to its pivotal Phase 2B/3 trial ("MIRACLE") evaluating Annamycin combined with cytarabine ("AnnAraC") for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company reported active site status and recruitment updates for the multi-center, randomized, double-blind, placebo-controlled, adaptive-design study. The MIRACLE trial is described as a global approval trial with sites in the U.S., Europe and the Middle East. A press release providing these trial updates is attached to the report as Exhibit 99.1 and is furnished with the filing.
Moleculin Biotech, Inc. filed a Current Report on Form 8-K disclosing that on September 8, 2025 the company posted and is using an Investor Presentation dated September 2025 as its corporate presentation and furnished that presentation as Exhibit 99.1. The filing states the furnished presentation is not being "filed" under the Exchange Act and will not be incorporated by reference into future filings unless expressly identified. The report identifies the registrant, principal executive office address in Houston, Texas, trading symbol MBRX on NASDAQ, and includes the Exhibit list and Inline XBRL cover page reference.
Moleculin Biotech announced the start of EU enrollment in its pivotal Phase 2B/3 trial of Annamycin combined with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company reported that the first two subjects in the European Union have been enrolled and one subject has been treated, marking initiation of EU participation in a multi-center, randomized, double-blind, placebo-controlled, adaptive-design study.
The press release is attached as an exhibit to the company's report and is being furnished rather than filed. The disclosure focuses on clinical development progress—specifically geographic expansion of patient enrollment in a late-stage trial evaluating Annamycin plus Ara-C for R/R AML.
Moleculin Biotech, Inc. has called a special stockholder meeting to approve several corporate actions. The main item seeks approval, for Nasdaq Listing Rule 5635(d) purposes, to allow the exercise of warrants for up to 64,864,864 shares of common stock issued in an August 28, 2025 private placement. These Series F warrants carry a $0.55 exercise price, a five‑year term from stockholder approval, anti‑dilution adjustments with a floor price of $0.11, and beneficial ownership limits of 4.99% or 9.99% at each holder’s election.
If fully exercised for cash at the initial exercise price, the company states it would receive approximately $35.7 million in proceeds, compared with 36,739,360 shares of common stock outstanding as of August 28, 2025. Stockholders are also being asked to approve changing the corporate name to Moleculin Inc. and to authorize potential adjournment of the meeting to solicit additional proxies if needed. The Board unanimously recommends voting in favor of all three proposals.
Moleculin Biotech, Inc. reported two corporate actions in this Current Report. Stockholders approved and the company filed a Certificate Amendment to increase authorized common shares from 100,000,000 to 500,000,000, which became effective upon filing with the Delaware Secretary of State on August 21, 2025. The company also furnished a press release dated August 27, 2025 announcing completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin combined with Cytarabine (referred to as AnnAraC) for treatment of subjects with acute myeloid leukemia (AML). The Certificate Amendment and the press release are attached as exhibits.
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K reporting a Regulation FD disclosure that the company posted an investor presentation dated August 2025 to its website and furnished the presentation as Exhibit 99.1. The filing clarifies the furnished exhibit is not being "filed" under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless expressly stated. No financial results, transactions, or forward-looking guidance are included in this report.
Moleculin Biotech, Inc. reported results from its annual meeting held August 18, 2025. Stockholders elected six directors to serve until the next annual meeting and approved several governance and compensation measures. Shareholders approved an amendment to the 2024 Equity Incentive Plan, a non-binding advisory vote on executive compensation, the issuance of up to 6,542,058 shares upon exercise of certain warrants issued February 26, 2025, an amendment increasing authorized common shares from 100,000,000 to 500,000,000, and an amendment granting the board authority to effect a reverse stock split. The proposal to eliminate supermajority voting requirements was not approved.
Vote totals are reported for each matter (for example, Proposal to increase authorized shares: 4,320,277 for, 1,697,864 against, 22,971 abstentions). The report was signed by the Chief Financial Officer.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,586,521 shares of Moleculin Biotech, Inc. common stock, representing 4.99% of the class. The filing states that Armistice Capital, as investment manager of its Master Fund, and Mr. Boyd as its managing member, exercise shared voting and dispositive power over these shares; neither reports sole voting or dispositive power. The Master Fund is identified as the direct holder while disclaiming direct beneficial ownership due to the investment management agreement. The statement affirms the holdings were acquired in the ordinary course of business.